

**UNDERTAKING TO FILE
MATERIAL CONTRACTS AND DOCUMENTS**

**To: *Autorité des marchés financiers*
(the “Principal Regulator”)**

Knight Therapeutics Inc. (the “**Issuer**”) is filing a short form base shelf prospectus dated December 21, 2020 (the “**Prospectus**”) with the Principal Regulator and with the securities regulatory authority in each of the other provinces of Canada.

The Issuer hereby undertakes, in accordance with sections 4.2(a)(x) and (x.1) of National Instrument 44-101 – *Short Form Prospectus Distributions* (“**NI 44-101**”) and section 7.1 of National Instrument 44-102 – *Shelf Distributions*, to file via SEDAR, (i) a copy of any agreement or contract referred to in section 4.2(a)(iii) or any material contract under section 4.2(a)(iii.1) of NI 44-101 that has not been executed before the filing of the Prospectus but will be executed on or before the completion of a distribution under the Prospectus, promptly and in any event no later than seven days after the execution of such agreement, contract or material contract and (ii) a copy of any document referred to in section 4.2(a)(iii) of NI 44-101 that does not need to be executed in order to become effective and has not become effective before the filing of the Prospectus, but will become effective on or before the completion of a distribution under the Prospectus, promptly and in any event no later than seven days after the document becomes effective.

[Signature on the following page]

DATED December 21, 2020

KNIGHT THERAPEUTICS INC.

Per: (signed) Arvind Utchanah
Arvind Utchanah
Chief Financial Officer